🔗 Share this article

A shadow market for unlicensed weight-loss drugs is being driven by social media fitness personalities and sellers on messaging platforms, according to new investigations.

Experimental Treatment Gaining Traction Via Social Media

Retatrutide, which remains in clinical trials, is being promoted by online personalities for its supposed weight-reducing properties. Followers are encouraged to message these profiles privately for supplier links, while also obtaining discount codes.

Thriving Trade on Messaging Platforms

Additionally, a flourishing trade exists on Telegram, where communities with thousands of participants share comparison images, administration instructions and assertions of next-day British shipping. Vendors market the substance there before redirecting buyers to WhatsApp for purchases.

Understanding The Experimental Drug

This medication is an experimental injection developed by American pharmaceutical company Eli Lilly. The treatment targets three gut hormones – GLP-1, glucose-dependent insulinotropic polypeptide and pancreatic hormone. Preliminary studies suggest it could assist patients reduce up to a quarter of their body weight. Referred to as the “triple G”, the drug is being hailed online as the next Ozempic.

Healthcare Professionals Voice Concerns

However, physicians and chemists have warned that the distribution of what is still an unlicensed medication in the United Kingdom is a cause for concern and could result in users injecting substances of uncertain source.

Some professionals stated the demand for retatrutide could be connected to the increasing price of approved slimming products such as Mounjaro.

Legal Position and Enforcement

Selling the unapproved drug on social media or Telegram is illegal in the UK, as it is an unlicensed drug that must not be marketed or supplied for personal consumption under the Human Medicines Regulations 2012.

Several influencers attempt to sidestep the rules by referring to the drug as a “research chemical” or citing it as “not for human consumption”. The substance is not a controlled drug, but promotion and supply can still breach medicines, advertising, and customer laws, potentially leading to penalties, prosecution or prison.

Platform Reaction and Material Removal

Based on the social media company, the service has taken down violative material and banned associated hashtags and search suggestions. The company stated it was committed to keeping the service safe and investing in enhancing enforcement strategies.

Online Marketplace Activities

Research also found groups with up to nine thousand members selling retatrutide using Telegram's built-in discovery tool, which functions like a public directory. Typing “retatrutide” immediately displays channels with numerous of users, populated with photos of weight loss, positive reviews and step-by-step instructions for mixing or injecting at residence.

Within moments of entering one group, a vendor posted WhatsApp details, where the majority of transactions occur. The seller sent an instruction manual and promised shipping within two days. When questioned whether the substance was authentic, one seller said: “You can’t be sure.” Another shared a photo of a supposed testing documentation. Not one asked about body mass, medical conditions or past usage.

Item Information and Costs

Inside these groups, messages show dark colored packages with postal service labels, claiming to include fresh supplies. One communication read: “It took eight of us to load them this morning.”

Buyers can select between dry substance containers, prepared at residence with purified liquid, or pre-filled injectors usually priced at £160 for 20 milligrams. When asked how much time a pen should last, vendors give contradictory responses varying between a several days to “depends on your body”.

Service Moderation and Safety Measures

A spokesperson for the messaging service said it regularly monitored dangerous content on its platform including material that encouraged the “misuse of controlled medications”. The organization added that it removed “millions of pieces of harmful content each day”.

Medical Expert Cautions

“Individuals are administering substances they cannot confirm. Even if the research behind this drug is sound, these digital versions may not contain what they advertise,” said Jason Murphy, the director of pharmaceutical services at Chemist4U.

Dr Crystal Wyllie of Asda Online Doctor linked the increase in interest to current price rises for authorized slimming medications such as Mounjaro. “With costs rising, patients are using online platforms. But counterfeit treatments are highly risky. You can’t be certain what’s inside or whether the environment they were produced in was clean,” she explained.

Her team has previously encountered patients harmed by personal administration from unverified suppliers. “We understand the disappointment, but buying from messaging apps or WhatsApp is gambling with your well-being,” stated Wyllie. “These substances could be impure or incorrectly dosed.”

Producer Statement

A representative from Eli Lilly stated retatrutide was in phase 3 clinical trials and had not been evaluated or approved by any regulatory agency globally. “Consequently at this time no one can sell [it] for personal consumption,” they explained, noting that any product “misleadingly claiming itself as a company investigational substance not yet authorized … may expose patients to possibly serious medical dangers”.